Live Analyst Rating Changes 1527 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Akinori Ueda
GS
Akinori Ueda
Goldman Sachs
Wall Street Analyst
Not yet ranked — too few measurable calls.
0%
Success Rate
-18.1%
Average Return
0 of 2 calls profitable · -33.6% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 0% of Akinori Ueda's ratings turned a profit when each position was held for 1 year — averaging -18.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

20 Buy 8 Hold 1 Sell
Akinori's Stock Coverage 17 ratings · 2026-06-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
JP:4507
Shionogi & Co
 Jun 15, 2026 BUY Buy
-2.5% avg upside
5 analysts
$3400.00
22.28% Upside
 ·
JP:7733
Olympus
 Jun 15, 2026 HOLD Strong Buy
+59.6% avg upside
4 analysts
$2050.00
24.95% Upside
 ·
JP:2413
M3
 Jun 15, 2026 HOLD Hold
+10.3% avg upside
1 analyst
$1800.00
10.33% Upside
 ·
JP:4519
Chugai Pharmaceutical Co
 Jun 15, 2026 BUY Strong Buy
+22.2% avg upside
5 analysts
$8950.00
20.60% Upside
 ·
LINK
Interlink Electronics
 Jun 15, 2026 BUY Strong Buy
+117.4% avg upside
16 analysts
 — ·
JP:4578
Otsuka Holdings Co
 Apr 30, 2026 BUY Strong Buy
+10.1% avg upside
5 analysts
$12400.00
18.61% Upside
 ·
JP:4568
Daiichi Sankyo Company
 Apr 15, 2026 BUY Strong Buy
+71.3% avg upside
6 analysts
$4300.00
68.03% Upside
 ·
JP:4587
Peptidream
 Feb 17, 2026 BUY Buy
+185.2% avg upside
2 analysts
$2750.00
189.20% Upside
 ·
JP:6869
Sysmex
 Feb 13, 2026 BUY Buy
+28.3% avg upside
2 analysts
$2000.00
46.66% Upside
 ·
JP:4151
Kyowa Kirin Co
 Dec 16, 2025 SELL Sell
-15.3% avg upside
4 analysts
$2250.00
9.38% Downside
 ·
ALKS
Alkermes
 Jul 19, 2023 BUY Strong Buy
-17.6% avg upside
34 analysts
$40.00
11.12% Downside
 -21.8%
JP:4502
Takeda Pharmaceutical Co
 Jan 13, 2022 HOLD Strong Buy
+6.8% avg upside
8 analysts
$3700.00
24.99% Downside
 ·
JP:4543
Terumo
 Dec 21, 2021 HOLD Strong Buy
+68.2% avg upside
4 analysts
$5000.00
126.23% Upside
 ·
JP:4523
Eisai Co
 Jun 16, 2021 HOLD Buy
+22.4% avg upside
5 analysts
 — ·
TAK
Takeda Pharmaceutical Company
 Apr 19, 2021 BUY Strong Buy
+19.9% avg upside
5 analysts
 — -14.5%
OLYMY
Olympus
 Dec 20, 2018 BUY Strong Buy
1 analyst
 — ·
JP:4503
Astellas Pharma
 Jun 08, 2018 HOLD Buy
-2.1% avg upside
5 analysts
 — ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Akinori Ueda — Frequently Asked Questions
How accurate are Akinori Ueda's stock ratings?
Based on the calls 13Foresight could measure, about 0% of Akinori's ratings were profitable over a one-year hold, with an average return of -18.1% per rating, or -33.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Akinori ranked on 13Foresight?
Akinori Ueda is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Akinori cover?
Akinori most recently has ratings on JP:4507, JP:7733, JP:2413, JP:4519, LINK, JP:4578, JP:4568, JP:4587, JP:6869, JP:4151, ALKS, JP:4502 and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.